We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+12.56%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$401M
AUM Growth
+$10.4M
Cap. Flow
+$8.42M
Cap. Flow %
2.1%
Top 10 Hldgs %
79.05%
Holding
28
New
4
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$11.8M
2
CLDX icon
Celldex Therapeutics
CLDX
+$10.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$8.57M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.93M
5
VKTX icon
Viking Therapeutics
VKTX
+$4.92M

Top Sells

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$11.9M
2
KYNB
Kyntra Bio
KYNB
+$10.8M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.92M
4
PEAR
Pear Therapeutics, Inc. Class A Common Stock
PEAR
+$4.27M
5
IRON icon
Disc Medicine
IRON
+$3.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
1
Enliven Therapeutics
ELVN
$4.15B
$118M 29.48%
5,798,475
– –
TRDA icon
2
Entrada Therapeutics
TRDA
$282M
$66.7M 16.63%
4,408,379
– –
IRON icon
3
Disc Medicine
IRON
$2.93B
$21.7M 5.4%
488,442
-100,000
-17% -$3.55M
RLYB icon
4
Rallybio
RLYB
$84.6M
$20.5M 5.12%
453,841
– –
VOR icon
5
Vor Biopharma
VOR
$1.16B
$19.7M 4.9%
318,086
– –
MLTX icon
6
MoonLake Immunotherapeutics
MLTX
$1.48B
$18.2M 4.54%
357,486
+318,630
+820% +$8.57M
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.89B
$15.5M 3.87%
862,286
– –
ZNTL icon
8
Zentalis Pharmaceuticals
ZNTL
$331M
$13.8M 3.44%
+490,000
New +$11.8M
SCPH
9
DELISTED
scPharmaceuticals
SCPH
$12.2M 3.05%
1,200,647
– –
CLDX icon
10
Celldex Therapeutics
CLDX
$2.96B
$10.5M 2.62%
+310,270
New +$10.5M
VKTX icon
11
Viking Therapeutics
VKTX
$3.8B
$9.48M 2.36%
585,000
+235,000
+67% +$4.92M
COGT icon
12
Cogent Biosciences
COGT
$6.64B
$9.36M 2.33%
790,440
– –
PHVS icon
13
Pharvaris
PHVS
$2.25B
$8.9M 2.22%
587,600
– –
ARVN icon
14
Arvinas
ARVN
$520M
$7.94M 1.98%
320,000
– –
RNAM
15
DELISTED
Avidity Biosciences
RNAM
$7.38M 1.84%
665,555
– –
ANAB icon
16
AnaptysBio
ANAB
$1.59B
$7.28M 1.81%
357,733
– –
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.96M 1.73%
+192,500
New +$7.93M
VRDN icon
18
Viridian Therapeutics
VRDN
$2.13B
$6.66M 1.66%
280,000
– –
SPRB
19
Spruce Biosciences
SPRB
$119M
$5.08M 1.27%
31,520
– –
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
$4.29M 1.07%
52,200
+4,800
+10% +$702K
QTTB icon
21
Q32 Bio
QTTB
$450M
$4.01M 1%
251,996
– –
IMPL
22
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$3.66M 0.91%
2,884,791
– –
GHRS icon
23
GH Research
GHRS
$1.93B
$1.8M 0.45%
+152,022
New +$1.56M
CDTX
24
DELISTED
Cidara Therapeutics
CDTX
$1.28M 0.32%
56,726
– –
KYNB
25
Kyntra Bio
KYNB
$27.4M
– –
-23,177
Closed -$10.8M
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q2 2023 Portfolio in Review

As of Q2 2023, 5AM Venture Management held 28 positions worth $401M, up 2.7% from $391M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

5AM Venture Management's Q2 2023 filing shows 4 new, 3 increased, 1 reduced and 4 closed positions. Its largest new stake was Zentalis Pharmaceuticals: 490,000 shares worth $13.8M. The largest sale was IDEAYA Biosciences, an estimated $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q2 2023 buy was Zentalis Pharmaceuticals: 490,000 shares worth $13.8M.
  • 5AM Venture Management added most to MoonLake Immunotherapeutics in Q2 2023, an estimated $8.57M increase.
  • 5AM Venture Management's biggest Q2 2023 reduction was Disc Medicine, cutting an estimated $3.55M.
  • 5AM Venture Management fully exited IDEAYA Biosciences in Q2 2023, selling an estimated $11.9M.
  • 5AM Venture Management's ten largest holdings make up 79% of its $401M portfolio in Q2 2023.
  • 5AM Venture Management opened 4 new positions and closed 4 in Q2 2023.
  • 5AM Venture Management's portfolio value rose 2.7% quarter-over-quarter to $401M.

Based on 5AM Venture Management's 13F filing for Q2 2023, filed 14 Aug 2023.